NYSE:CPHI
China Pharma Holdings, Inc.
China Pharma Holdings, Inc.'s revenue fell 8.5% in fiscal 2025 to $4.1M while operating margin rose to −78.2%. Free cash flow was $88,937, 2.1% of revenue.Summary generated from China Pharma Holdings, Inc.'s SEC filings. Latest annual report filed Apr 1, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.1M
Revenue growth−8.5%
Revenue, 5-yr CAGR−17.5%
Gross margin−3.2%
Operating margin−78.2%
Net margin−76.9%
ROIC−15.9%
Return on equity−20.9%
Debt / equity0.06
Free cash flow$88,937
FCF margin2.1%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 | 8 | 7 | 5 | 4 |
| Operating income | −3 | −4 | −3 | −5 | −3 |
| Net income | −3 | −4 | −3 | −5 | −3 |
| Free cash flow | −1 | −1 | −1 | −0 | 0 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KEntry into a material agreement
Jul 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Apr 1, 2026 - 8-KEntry into a material agreement
Mar 3, 2026 - 8-KEntry into a material agreement
Feb 10, 2026 - 8-KResults of a shareholder vote
Jan 6, 2026 - 8-KEntry into a material agreement
Dec 23, 2025